Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Cladribine is a synthetic purine analogue that interferes with DNA synthesis and repair next to disrupting cellular proliferation in actively dividing lymphocytes. The compound is approved for the treatment of multiple sclerosis (MS). Cladribine can cross the blood-brain barrier, suggesting a potential effect on central nervous system (CNS) resident cells. Here, we explored compartment-specific immunosuppressive as well as potential direct neuroprotective effects of oral cladribine treatment in experimental autoimmune encephalomyelitis (EAE) mice.

Methods: In the current study, we compare immune cell frequencies and phenotypes in the periphery and CNS of EAE mice with distinct grey and white matter lesions (combined active and focal EAE) either orally treated with cladribine or vehicle, using flow cytometry. To evaluate potential direct neuroprotective effects, we assessed the integrity of the primary auditory cortex neuronal network by studying neuronal activity and spontaneous synaptic activity with electrophysiological techniques ex vivo.

Results: Oral cladribine treatment significantly attenuated clinical deficits in EAE mice. Ex vivo flow cytometry showed that cladribine administration led to peripheral immune cell depletion in a compartment-specific manner and reduced immune cell infiltration into the CNS. Histological evaluations revealed no significant differences for inflammatory lesion load following cladribine treatment compared to vehicle control. Single cell electrophysiology in acute brain slices was performed and showed an impact of cladribine treatment on intrinsic cellular firing patterns and spontaneous synaptic transmission in neurons of the primary auditory cortex. Here, cladribine administration in vivo partially restored cortical neuronal network function, reducing action potential firing. Both, the effect on immune cells and neuronal activity were transient.

Conclusions: Our results indicate that cladribine exerts a neuroprotective effect after crossing the blood-brain barrier independently of its peripheral immunosuppressant action.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641831PMC
http://dx.doi.org/10.1186/s12974-022-02588-7DOI Listing

Publication Analysis

Top Keywords

cladribine treatment
20
immune cell
12
cladribine
11
autoimmune encephalomyelitis
8
blood-brain barrier
8
potential direct
8
direct neuroprotective
8
neuroprotective effects
8
oral cladribine
8
eae mice
8

Similar Publications

Hairy cell leukemia (HCL) is a rare, indolent lymphoproliferative disorder that is highly responsive to purine analog therapy. While agents such as cladribine and pentostatin remain standard front-line therapies, their long-term toxicities-particularly myelosuppression and immune dysfunction-have led to growing interest in chemotherapy-free agents. Recent advances in molecular characterization of HCL, including the near-universal presence of BRAF V600E mutations, have led to an era of targeted therapeutics for the treatment of this disease.

View Article and Find Full Text PDF

: Multiple sclerosis (MS) is a chronic immune-mediated neurological disorder that primarily affects young adults and is frequently accompanied by psychiatric comorbidities such as depression and anxiety, both of which significantly diminish patients' quality of life (QoL). This study investigated the effect of two oral disease-modifying therapies (DMTs), fingolimod and cladribine, on mental health and QoL in patients with relapsing-remitting MS (RRMS). The aim of the study was to compare levels of depression, anxiety, and health-related quality of life (HRQoL) in RRMS patients treated with fingolimod or cladribine, and to evaluate their associations with clinical and radiological parameters.

View Article and Find Full Text PDF

Cladribine (2-chlorodeoxyadenosine or 2CdA) is a purine analogue that has been used in various non-Langerhans cell histiocytosis. We present a case series of six patients with xanthoma disseminatum having systemic involvement, treated with monthly cladribine for three to 12 cycles (median six cycles), leading to 63.3% improvement at the end of treatment, increasing to 75% at the end of 2.

View Article and Find Full Text PDF

Langerhans cell histiocytosis (LCH) is a proliferative disorder causing normally immune-responsive Langerhans cells to abnormally accumulate in various tissues and organs. Most available data on LCH is derived from pediatric populations, with limited literature focusing on adult LCH, which is rarer. Multisystem involvement in LCH, including central nervous system (CNS) involvement, is often higher risk and poorer prognosis.

View Article and Find Full Text PDF

Management of hairy cell leukaemia in pregnancy.

Obstet Med

August 2025

Department of Obstetrics, Western Health, St Albans, Australia.

Background: Hairy cell leukaemia (HCL) represents less 1% of all lymphoid neoplasms with cases rarely reported in pregnancy. Management of HCL requires multidisciplinary care to optimise maternal and neonatal outcomes.

Methods: A literature search of Ovid MEDLINE and EMBASE for 'hairy cell leukaemia' and 'Pregnancy' was undertaken.

View Article and Find Full Text PDF